In addition, the ability of NUSAP1 as a biomarker to predict the efficacy of PARP inhibitors alone or in combination with DNMT inhibitions warrants further evaluation, which will assist in the development of future individualized therapeutic strategies for ovarian cancer. The gene discussed is NUSAP1; the disease is ovarian carcinoma.